Omeros reported $-47.96M in EBITDA for its fiscal quarter ending in September of 2023.





Ebitda Change Date
Adma Biologics USD 55.44M 5.62M Jun/2026
Alnylam Pharmaceuticals USD 360.27M 114.93M Sep/2026
BioMarin Pharmaceutical USD 222.32M 76.27M Jun/2026
Cytokinetics USD -160.3M 9.02M Jun/2026
Gilead Sciences USD -9.31B 12.82B Jun/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Immunic USD -22.78M 753K Jun/2024
Insmed USD -80.97M 93.7M Sep/2026
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
MacroGenics USD -64.54M 34.34M Jun/2026
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.36B 350M Sep/2026
Sarepta Therapeutics USD -3.14M 33.31M Sep/2026
United Therapeutics USD 334.2M 20.8M Sep/2026
Vertex Pharmaceuticals USD 1.33B 130.5M Jun/2026